CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 82 enrolled
Drug / intervention
Cardiac resynchronization therapy pacemaker (CRT-P)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03420833
NCT03420833N/ACompleted
CompareCT.gov

Metabolic Mapping and Cardiac Resynchronization (Aim 1)

Yong-Mei Cha·interventional·Posted Feb 5, 2018·Updated Jan 23, 2025

In Brief

A clinical study evaluating Cardiac resynchronization therapy pacemaker (CRT-P) for Heart Failure. Completed, enrolled 82 participants across 1 site.

Detailed Summary

The purpose of this study is to gather information on the safety and effectiveness of cardiac resynchronization therapy (CRT) in patients who have mild heart failure (HF) and left bundle branch block (LBBB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Biotronik SE & Co. KG

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 5, 2018
Enrollment StartAug 20, 2018
Primary CompletionDec 19, 2023
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 8.4 years ago

Interventions

Cardiac resynchronization therapy pacemaker (CRT-P)device

A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.